Aligos Therapeutics presented positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025. Preliminary data for ALG-000184 for chronic hepatitis B virus (HBV) infection extended to 96 weeks in its Phase 1 study. This data showed 100% HBV DNA suppression in HBeAg-positive subjects (9/9) and sustained HBV DNA suppression in HBeAg-negative subjects by Week 24, maintained for up to 96 weeks.
No viral resistance or breakthrough was observed with ALG-000184 monotherapy over the 96-week dosing period. Multi-log reductions in HBV antigens (HBsAg, HBeAg, and HBcrAg) were observed, indicating the activation of the CAM-E second mechanism. The drug continued to be well tolerated in both patient populations.
Additionally, the company highlighted the best-in-class potential of ALG-055009 for MASH, reiterating robust reductions in liver fat content from the Phase 2a HERALD study. A subgroup analysis in subjects on stable GLP-1 agonist therapy showed a potential role for ALG-055009 in combination with other therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.